Share your videos with the world

Georgia Power today marked another year of safe construction and significant milestones at the Vogtle nuclear expansion site. The new units are currently scheduled to go into service in June 2019 (Unit 3) and June 2020 (Unit 4) and the remaining projected customer rate impact is approximately 2.5 percent, an average of less than 1 percent per year through completion. In addition, the company’s recent completion of the settlement process between the project co-owners (Georgia Power, Oglethorpe Power Corporation, the Municipal Electric Authority of Georgia and Dalton Utilities) and the project’s contractors (Westinghouse and CB&I) settles all claims previously in litigation with the contractors, reaffirms the current in-service dates, adds additional contractual protections and positions Westinghouse and its affiliates as the primary contractor over the project. To view the multimedia release go to: http://www.multivu.com/players/English/7464951-ga-power-project-vogtle/

The following statement is being issued by Branstetter, Stranch & Jennings, PLLC regarding In re Prograf Antitrust Litigation. A lawsuit is currently pending claiming that Astellas Pharma US, Inc. (“Astellas” or “Defendant”) violated state antitrust, unfair competition, consumer protection, and unjust enrichment laws of certain states by delaying the availability of a less expensive generic version of the immunosuppressant prescription drug Prograf® (known as tacrolimus). Plaintiffs allege that Defendant’s conduct caused some consumers and third party payors to pay too much for Prograf in certain states from September 3, 2008 to December 31, 2010 (also referred to as the “Class Damage Period”). This lawsuit does not claim that Prograf is unsafe or ineffective. Astellas denies any wrongdoing. To view the multimedia release go to: http://www.multivu.com/players/English/7933851-prograf-antitrust-class-action-settlement/